title: SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.
abstract: OBJECTIVE
  Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response.
  
  
  METHODS
  Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Positive and Negative Syndrome Scale total score) among European ancestry patients treated with paliperidone extended release (n=937), paliperidone palmitate (n=990), risperidone (n=507) and olanzapine (n=381) in 12 schizophrenia, two schizoaffective disorder and three bipolar I disorder trials. SULT4A1-1 haplotype was determined using tagging SNP rs763120.
  
  
  RESULTS
  There was no significant difference between SULT4A1-1(+) and SULT4A1-1(-) patients for treatment response to paliperidone or olanzapine. SULT4A1-1(-) patients had better treatment response to risperidone in one schizophrenia trial, but not in another schizophrenia trial or bipolar mania trial.
  
  
  CONCLUSIONS
  Across three psychiatric disorders (n=2815 patients), we observed no consistent association between SULT4A1-1 status and atypical antipsychotic effect.
authors.affiliation: Neuroscience Therapeutic Area, Janssen Research & Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ, USA.
authors.forename: Dai
authors.initials: D
authors.lastname: Wang
authors.forename: Qingqin
authors.initials: Q
authors.lastname: Li
authors.forename: Reyna
authors.initials: R
authors.lastname: Favis
authors.forename: Andrew
authors.initials: A
authors.lastname: Jadwin
authors.forename: Hedy
authors.initials: H
authors.lastname: Chung
authors.forename: Dong-Jing
authors.initials: DJ
authors.lastname: Fu
authors.forename: Adam
authors.initials: A
authors.lastname: Savitz
authors.forename: Srihari
authors.initials: S
authors.lastname: Gopal
authors.forename: Nadine
authors.initials: N
authors.lastname: Cohen
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage; D001569:Benzodiazepines / Q000008:administration & dosage; D054316:Biomarkers, Pharmacological; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D056726:Genetic Association Studies; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D000077152:Olanzapine; D018967:Risperidone / Q000008:administration & dosage; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015238:Sulfotransferases / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D054316:Biomarkers, Pharmacological; D001569:Benzodiazepines; C479953:SULT4A1 protein, human; D015238:Sulfotransferases; D018967:Risperidone; D000077152:Olanzapine
keywords: PANSS; SULT4A1; antipsychotic response; haplotype; olanzapine; paliperidone; risperidone; schizophrenia